News and Announcements
EPIAXIS THERAPEUTICS APPOINTS DR DARREN SAUNDERS AS CHIEF SCIENCE OFFICER
- Published April 21, 2022 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
EpiAxis Therapeutics has welcomed biomedical scientist Dr Darren Saunders as its new Chief Science Officer.
The appointment follows Dr Saunders joining EpiAxis Therapeutics in October 2021 as Science and Communications Advisor.
Dr Saunders is a research scientist specialising in cancer biology, Associate Professor in Medicine at the University of Sydney and Senior Research Advisor to Elizabeth Broderick and Co. He undertook post-doctoral training at the Garvan Institute and University of British Columbia and has held fellowships from the US Dept. of Defense and Cancer Institute NSW.
Dr Saunders has made significant contributions to leadership, governance and engagement through peak professional bodies and policy development. He is a regular commentator on television and radio, resident scientist on ABC TV’s The Drum and Channel 7’s Daily Edition, and 2019 Eureka Prize winner.
“We are delighted that a scientist and skilled communicator of Dr Saunders’ calibre has chosen to join EpiAxis as its Chief Science Officer,” EpiAxis Therapeutics CEO Dr Jeremy Chrisp said. “His appointment is another significant step in the development of our Company as we continue to progress our epigenetic pipeline.”
Dr Saunders said he was excited to expand his role with EpiAxis Therapeutics during its mission to reprogram cancer and immune cells with next generation therapeutics.
“I’m excited to be joining EpiAxis at an important time for the company,” he said. “I’m really looking forward to advancing the development of new therapeutic strategies for cancer in the rapidly evolving epigenetic space.”
ABOUT EPIAXIS THERAPEUTICS:
EpiAxis is a leading drug development company that aims to make cancer a chronic disease rather than a fatal one, by using epigenetic science to create a completely different approach to cancer treatment. Our therapies work differently to existing – and often toxic – treatments by uniquely reprogramming the cancer cells back towards normal cells.
Company Updates
Accessing Private Equity Opportunities at Emergence 2025
Explore the five trends redefining private equity in 2025, from wealth transitions to the rise of search funds. Join industry leaders at Emergence 2025 to gain exclusive insights and refine your investment strategies.
Why Are Fewer Companies Going Public?
The number of companies listing on the ASX has declined, driven by access to private capital, regulatory burdens, and market volatility. However, public markets still offer liquidity, visibility, and robust capital-raising opportunities.
A Message to Founders: A Shared Journey to 2025 – A Once in a Generation Opportunity
As we close this challenging year, let’s reflect on the resilience, lessons, and growth that brought us here. Founders, 2025 is your golden opportunity to innovate, scale, and thrive. Set your strategy, rest, and prepare to sprint into a year of unparalleled possibilities.
Backed By Leading Investment Groups and Family Offices
